The ICU-ROX Trial will test the hypothesis that, compared to a liberal approach, a conservative approach to oxygen delivery may reduce lung collapse (atelectasis), decrease the risk of new non- respiratory organ dysfunction, and might reduce 28-day mortality.
The ICU-ROX Trial
More than 20,000 New Zealanders are admitted to an intensive care unit (ICU) annually. ICU patients are the sickest patients in the hospital and many require life support (mechanical ventilation).
Although supplemental oxygen is universally delivered to patients who require mechanical ventilation in the ICU, there is no level I evidence with respect to the most appropriate ‘dose’ of oxygen to provide to these patients.
It is generally accepted that abnormally low levels of oxygen should be avoided where possible; however, there is no consensus regarding the approach to abnormally high levels of oxygen in patients who require mechanical ventilation
Primary: To determine whether a conservative approach to oxygen therapy, which minimises unnecessary exposure to hyperoxaemia, will increase day 90 survival compared to a more liberal approach to oxygen therapy which does not specifically aim to avoid exposure to hyperoxaemia.
the study is a multicentre, parallel group randomised controlled superiority trial which will allocate ICU patients in a 1:1 ratio to liberal or conservative oxygen therapy
the study will compare two approaches to oxygen therapy in adults requiring mechanical ventilation in the ICU
the study will be conducted in ICUs in Australia and New Zealand
Supported by the Health Research Council of New Zealand
Coordinating centre: The Medical Research Institute of New Zealand
Chief Investigator: Dr Paul Young, Specialist in Intensive Care Medicine, Wellington Hospital
Read what people are saying about the ICU-ROX Trial on Twitter
Read what people are saying about the ICU-ROX Trial on Twitter.